Research progress of Chinese and Western medicine treatment of patients with heart failure with reduced ejection fraction
Z HOU Ling1 LI Huabo2▲
1. Department of Medicine, Hubei Minzu University, Hubei Province, Enshi 445000, China; 2. Department of Cardiology, Minda Hospital Affiliated to Hubei Minzu University, Hubei Province, Enshi 445000, China
Abstract：According to the level of left ventricular ejection fraction (LVEF), heart failure (HF) can be divided into heart failure with reduced ejection fraction (HFrEF), heart failure with retained ejection fraction (HFpEF) and heart failure with median ejection fraction (HFmrEF). HFrEF is the main type of HF, and its incidence is increasing year by year. Although the combination of existing traditional drugs for the treatment of HFrEF can delay the course of the disease and improve the symptoms and prognosis of patients to a certain extent, there are many adverse reactions of traditional drugs, the treatment effect of HFrEF is limited, and the complications or complications of HFrEF can not be effectively treated, and the rehospitalization rate and mortality rate of patients are still high. Recently, with the further research and exploration of the occurrence and development of HFrEF and the mechanism of drug action, a variety of Chinese and Western drugs have been developed to make up for the deficiency of traditional drugs in the treatment of HFrEF.In this paper,the treatment of HFrEF Chinese and Western medicine representative drugs Ivabradine,Shakubaqu Valsartan, Aliskiren, Shexiang Baoxin Pills, Qili QiangXin Capsule pharmacological characteristics and treatment progress were reviewed.
周 玲；李华波. 射血分数降低的心力衰竭患者的中西药治疗研究进展[J]. 中国当代医药, 2022, 29(4): 29-32.
Z HOU Ling；LI Huabo. Research progress of Chinese and Western medicine treatment of patients with heart failure with reduced ejection fraction. 中国当代医药, 2022, 29(4): 29-32.
Maagaard M，Nielsen EE，Gluud C，et al.Ivabradine for coronary artery disease and/or heart failure-a protocol for a systematic review of randomised clinical trials with metaanalysis and Trial Sequential Analysis[J].Syst Rev，2019，8（11）：39-41.
[6]
Kiuchi S，Hisatake S，Kabuki T，et al.Efficacy and Safety of Ivabradine in an Elderly Patient with Heart Failure with Reduced Ejection Fraction[J].Clin Drug Investig，2021，41（13）：193-196.
[7]
Komajda M，Isnard R，Cohen-Solal A，et al.Effect of ivabradine in patients with heart failure with preserved ejection fraction：the EDIFY randomized placebocontrolled trial[J].Eur J Heart Fail，2017，19（11）：1495-1503.
[8]
Gregorietti V，Fernandez TL，Costa D，et al.Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy[J].CardioOncology，2020，6（12）：24-26.
[9]
Polito MV，Silverio A，Rispoli A，et al.Clinical and echocardiographic benefit of Sacubitril/valsartan in a realworld population with HF with reduced ejection fraction[J].Sci Rep，2020，10（1）：6665.
[10]
Moliner-Abós C，Rivas-Lasarte M，Pamies Besora J，et al.Sacubitril/valsartan in real-life practice：experience in patients with advanced heart failure and systematic review[J].Cardiovasc Drugs Ther，2019，33（3）：307-314.
[11]
Sauer AJ，Cole R，Jensen BC，et al.Practical guidance on the use of sacubitril/valsartan for heart failure[J].Heart Fail Rev，2019，24（10）：167-176.
[12]
De Vecchis R，Paccone A，Di Maio M.Sacubitril/valsartan for heart failure with reduced left ventricular ejection fraction[J].Herz，2019，44（15）：425-432.
[14]
Gaziano TA，Fonarow GC，Velazquez EJ，et al.Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction[J].JAMA Cardiol，2020，5（11）：1236-1244.
[16]
Kristensen SL，Mogensen UM，Tarnesby G，et al.Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes：a subgroup analysis from the ATMOSPHERE trial[J].Eur J Heart Fail，2017，20（1）：136-147.
[17]
Zhao Q，Shen J，Lu J，et al.Clinical efficacy，safety and tolerability of Aliskiren Monotherapy （AM）：an umbrella review of systematic reviews[J].BMC Cardiovasc Disord，2020，20（2）：179-182.
京公网安备 11010502046607号